abstract |
The present disclosure is directed to compositions and methods for treating presbyopia. The compositions can include a cholinesterase inhibitor, such as neostigmine, echothiophate, diisopropyl fluorophosphates, or physostigmine, and/or a mitoic agent. The compositions can act alone or synergistically, for example, to improve the accommodative and focusing ability of the eye while minimizing the side effects from each compound. |